16D0 Waldman, Scott - Thomas Jefferson University - Thomas Jefferson University
saw103

Scott A. Waldman, MD, PhD

Contact Dr. Waldman

132 South Tenth Street
1170 Main Building
Philadelphia, PA 19107

(215) 955-6086
(215) 955-5681 fax

Most Recent Peer-reviewed Publications

  1. A novel CDX2 isoform regulates alternative splicing
  2. Tumor radiation therapy creates therapeutic vaccine responses to the colorectal cancer antigen GUCY2C
  3. Managing the innovation supply chain to maximize personalized medicine
  4. Antiobesity pharmacotherapy: New drugs and emerging targets
  5. GUCY2C lysosomotropic endocytosis delivers immunotoxin therapy to metastatic colorectal cancer
  6. Policies to aid the adoption of personalized medicine
  7. Selective antigen-specific CD4+ T-cell, but not CD8+ T- or B-cell, tolerance corrupts cancer immunotherapy
  8. Molecular insights provide the critical path to disease mitigation
  9. Erratum: Cardiopoietic stem cell therapy in heart failure: The C-CURE (Cardiopoietic stem Cell therapy in heart failURE) Multicenter randomized trial with lineage-specified biologics (Journal of the American College of Cardiology ( 1215 2013) 61 (2329-2338))
  10. Genetics and genomics for the prevention and treatment of cardiovascular disease: Update a scientific statement from the american heart association
  11. Reply: The C-CURE randomized clinical trial (Cardiopoietic stem Cell therapy in heart failURE)
  12. Intestinal GUCY2C prevents TGF-β secretion coordinating desmoplasia and hyperproliferation in colorectal cancer
  13. Advances in cancer immunotherapy
  14. Colorectal cancer immunotherapy
  15. Translating colorectal cancer prevention through the guanylyl cyclase C signaling axis
  16. Evidence-based guidelines for precision risk stratification- based screening (PRSBS) for colorectal cancer: Lessons learned from the us armed forces: Consensus and future directions
  17. Molecular staging of node negative patients with colorectal cancer
  18. Systems approaches evolve clinical pharmacology
  19. Cardiopoietic stem cell therapy in heart failure: The C-CURE (cardiopoietic stem cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics
  20. Dexamethasone-loaded block copolymer nanoparticles induce leukemia cell death and enhance therapeutic efficacy: A novel application in pediatric nanomedicine
0